Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.
Cancer immunology, immunotherapy : CII
Autoantibody Landscape in Patients with Advanced Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.
Cancer immunology research
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Ce...
TIICs will be analyzed by immunohistochemistry (IHC) in pre- and post-pembrolizumab-based treatment tumor specimens. The proportion of participants with a >=2-fold increase (from pre- to post-treatment) in the number of TIICs will...
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in ...
Dose limiting toxicity (DLT) is defined as protocol-defined adverse events that occur within 28 days following infusion of Neo-TCR-P1 administered as a single agent without or with IL-2, or in combination with nivolumab.
Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Adva...
DLTs will be assessed during the first cycle (21 days) & are defined as: Grade (Gr) 4 nonhematologic toxicity; Gr 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia, Gr 4 thrombocytopenia, Gr 3 thrombocytopenia (if as...
Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumor...
The proportion of participants who show clinical benefit, defined as complete response (CR), partial response (PR), or stable disease (SD) for ≥ 6 months as best response by RECIST v1.1